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Background: Inhibitors of pancreatic alpha-amylase are potential drugs to treat diabetes and obesity. In order to
find compounds that would be effective amylase inhibitors, in vitro and in vivo models are usually used. The
accuracy of models is limited, but these tools are nonetheless valuable. In vitro models could be used in large
screenings involving thousands of chemicals that are tested to find potential lead compounds. In vivo models are
still used as preliminary mean of testing compounds behavior in the whole organism. In the case of alpha-amylase
inhibitors, both rats and rabbits could be chosen as in vivo models. The question was which animal could present
more accuracy with regard to its pancreatic alpha-amylase.
Results: As there is no crystal structure of these enzymes, a molecular modeling study was done in order to
compare the rabbit and rat enzymes with the human one. The overall result is that rabbit enzyme could probably
be a better choice in this regard, but in the case of large ligands, which could make putative interactions with
the −4 subsite of pancreatic alpha-amylase, interpretation of results should be made cautiously.
Conclusion: Molecular modeling tools could be used to choose the most suitable model enzyme that would help
to identify new enzyme inhibitors. In the case of alpha-amylase, three-dimensional structures of animal enzymes
show differences with the human one which should be taken into account when testing potential new drugs.
Keywords: Rat alpha-amylase, Rabbit alpha-amylase, Amylase inhibitor, Homology modeling, DockingBackground
Carbohydrate digestion has been targeted as a mean to
control both postprandial increase of blood glucose and
weight gain [1]. Inhibitors of carbohydrate digesting
enzymes, such as alpha-amylase and alpha-glucosidase,
are now actively searched for, since they could ultimately
make useful medicines against diabetes and obesity [2,3].
There are numerous examples where inhibitors that were
found to be effective on glycosidic enzymes in vitro [4-7],
proved to possess hypoglycemic and weight decreasing
effect in vivo [5,7-9]. Pancreatic alpha-amylase inhibitors
could be foreseen to become part of the drugs used for
the so-called “diabesity” state. This enzyme inhibitors are* Correspondence: yaghmaei_p@srbiau.ac.ir
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distribution, and reproduction in any mediumespecially of interest, as they have been reported to be de-
void of the disturbing gastro-intestinal side-effect of some
alpha-glucosidase inhibitors [10,11].
Although the final target of this compounds is usually
the human pancreatic alpha-amylase, it is still common
place to use similar enzymes as models in the in vitro stud-
ies [5,6]. In the next level, use of animal models is also a
common method to assess the effect of these compounds,
and in most of these studies, rats are privileged, as access-
ible, established and reproducible models of diabetes and
obesity. There are also other alternatives, such as the possi-
bility of using rabbits [12], it would be thus interesting
to see which animal’s pancreatic enzyme is more similar
to the human one, and how this similarity/ difference
would affect the possibility of extrapolating the outcome of
animal tests to human beings. Since there is no crystal
structure of rat and rabbit enzymes, computer-generateded Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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rat, and human pancreatic enzymes with regard to their




Sequences of rabbit (Oryctolagus cuniculus_protein
accession number: XP_002715871) and rat (Rattus
norvegicus_protein accession number: P00689) enzymes
were retrieved from the NCBI (protein) (www.ncbi.nlm.
nih.gov). The 3OLD.pdb file of the human enzyme was
used to assess the length of the signal peptide, which was
omitted in the alignments. ClustalW [13] and the BLAST
tool of the NCBI site were used to perform alignments.
The BLAST program compares the protein sequences and
calculates the statistical significance of sequences that are
matched together, and reports the percentage of “identity”
(residues that are identical) and “similarity” (residues that
are conserved), which have been mentioned in the Results
section. Clustal W was used to make a multiple alignment
in order to have an insight into areas of similarity (usually
associated with conserved functional domains) as well as
differences that occur as a consequence to substitutions
and deletions of amino acids.
Model generation
The ModWeb server version SVN.r1368M (web based
version of Modeller [14]) was used in order to make the
rabbit and rat pancreatic amylase model (https://modbase.
compbio.ucsf.edu/scgi/modweb.cgi). Modeller performs
comparative modeling by satisfaction of spatial restraints
[15]. The program uses the protein sequence, and a three-
dimensional structure that has a high enough similarity to
the sequence to make a three-dimensional protein model.
In this case 1hx0.pdb corresponding to a porcine alpha-
amylase with 1.38 Å resolution was used. Usually, 30% of
identity between template and target is sufficient to obtain
a reliable model [16]; in this case, percentage of identical
residues of human and porcine enzymes with rat and
rabbit is higher than 80%. Although multiple alpha-
amylase structures have been elucidated, at the time this
study has been done, the 1hx0.pdb structure had the best
resolution between available mammalian alpha-amylase
structures. The sequence of rat and rabbit alpha-amylase
were given to the server, and the resulting models were
retrieved. Model quality was assessed with the Molprobity
[17] server, which analyses side chain rotamers and pro-
vide Ramachandran plots, which are indicative of the geo-
metrical parameters of the model.
Docking and molecular dynamics simulation
Docking was performed with Autodock vina [18]. The
3OLI.pdb file was first processed with the use of MOE2009.10 (Chemical Computing Group Inc., Montreal,
Canada). Additional molecules to alpha-amylase, including
solvent, were deleted prior to docking. MGLtools (v. 15.4,
revision 24) which is the graphical interface to Autodock
was used to define the docking box and assign gasteiger
charges to protein and ligand molecules. The docking box
was positioned at x = −8.548, y = −21.483, z = 18.925 with a
size of 64x82x58. A configuration file was prepared as the
input of Autodock vina. In addition to the docking box
specifications, in this configuration file, exhaustiveness
(related to the docking precision and usually set at 8) was
set on 20 and 100 poses were generated for the ligand. To
validate the docking method that was used, RMSD be-
tween actual pose of the co-crystallized ligand and docked
one was assessed with the use of the Profit server (http://
www.bioinf.org.uk/software/profit) which is based on the
McLachlan algorithm [19]. The default method was used
with inclusion of heteroatoms only and calculating RMSD
for all atoms.
The dynamics simulation module of MOE 2009.10 was
used to perform a short simulation of 5000 picoseconds
length with T = 300K using the Noise-Poicare-Andersen
Hamiltonian equations of motion. The protein was first
minimized. Then solvation was done with 17725 water
molecules. A preliminary simulation of t = 100 picoseconds,
T = 300K was performed to equilibrate the system, and
the output was used as the input of the actual 5000
picoseconds run. Sampling was done at each 5 picoseconds.
The MMFFx94 forcefield was used for all the calculations.
Results and discussion
The first stage in the process of choosing the more suit-
able model between rat (RPA) and rabbit (RABPA)
enzymes is the comparison of their amino acid sequences
with the human one (HPA). Figure 1 shows the result of a
multiple alignment between the three sequences. A pair-
wise alignment performed with BLAST reveals that the
rat and human enzyme have 84% identities and 92% simi-
larity. For the rabbit enzyme these figures become 87%
and 92% respectively. However, beside the higher iden-
tities of the rabbit and human enzyme, it is interesting to
notice the presence of a gap in the rat sequence, which is
located at the position of amino acids 143–145 of HPA
and RABPA. This gap makes the rat alpha-amylase 3
residues shorter than the human and rabbit one. The same
gap is seen in the mouse sequence. This sequence is TGS
in HPA and SGS in RABPA, which could be estimated to
be conserved between human and rabbit enzymes. The
TGS sequence is also detected in primates (e.g. Macaca
mulatta, Gorilla gorilla), Equus caballus, Bos taurus, Canis
familiaris, Taeniopygia guttata, monodelphis domestica,
Danio rerio, Myxocyprinus asiaticus, and Xenopus
tropicalis; as TAS in Sus scrofa, Meleagris gallopavo,
and Gallus gallus, and as TYS in Anolis carolinensis.
Figure 1 Results of the ClustalW [13] alignment for the pancreatic alpha-amylase amino acid sequences of human, rabbit (Oryctolagus
cuniculus), and rat (Rattus norvegicus) enzymes. Conserved regions are shown with asterisk. Colour codes of amino acids are as follows:
residues A,V,F,P,M,I,L, and W (small + hydrophobic (incl.aromatic -Y))in red, residues Dand E (acidic) in blue, residues R and K (basic) in magenta,
residues S,T,Y,H,C,N,G, and Q (Hydroxyl + sulfhydryl + amine + G) in green.
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for RPA and RABPA. It should be mentioned that the ter-
tiary structure of mammalian alpha-amylase has been
reported only for human salivary and pancreatic enzyme,
as well as porcine pancreatic enzyme. Small differences in
the spatial arrangement of residues (in similar enzymes)
could produce large effects on their interactions with
potential ligands [20], and the fact that proteins belong
to the same family is not enough to predict their ligand
binding profile [21]. In the absence of an experimentally
obtained structure, the best way to detect these differences
is to study a model. Protein models that are made by
comparative modeling are considered to be highly reliable,
especially when the percentage of identical residues is
elevated [16]. The template used to model RPA and
RABPA was the 1hx0.pdb [22] structure which originally
contained a carbohydrate-based ligand derivated from
acarbose. As mentioned in the Methods section, this
structure had the highest resolution in mammalian alpha-
amylases structures of the protein database (PDB), at the
time this study was performed. No missing atoms were
detected in this template. Ramachandran plot of 1 h × 0.
pdb indicates that 100% of its residues are situated in the
allowed region. RPA and RABPA models were generated
by the ModWeb server and subsequently minimized in
MOE. Quality assessment of the generated models
indicated them to be reliable. First, the results of evalu-
ation methods that are implemented within the ModWeb
server output were acceptable. The GA341 score was 1.0
for both models which is indicative of a reliable fold
(GA341 > 0.7 is related to ≥ 95% probability of correctFigure 2 Superimposed backbone structures of human (red
ribbons), rabbit (green ribbons), and rat (blue ribbons)
pancreatic alpha-amylases. Human structure is obtained from the
3OLI.pdb file, and rabbit and rat enzymes are modeled. The three
main domains of the enzymes are indicated (A,B, and C). The two
spheres are one calcium (in the left side of the picture, yellow) and
one chloride atom (in the center, cyan), which are located in their
conserved position among all three enzymes. The arrow indicated
the shorter loop of the rat enzymes which lacks residues 143–145 of
human and rabbit enzymes.fold). The MPQS (ModPipe Quality Score) was 1.96 for
RABPA and 2.08 for RPA which is a further approval of
the reliability of the model (MPQS value higher than 1.1
is indicative of a reliable model) [14]. Furthermore, as a
mean to assess the geometrical validity of the models.
Ramachandran plots [23] of RABPA and RPA were
obtained from the MolProbity server. Ramachandran
graphs of the two models indicated that for RABPA
99.8% (492/493) of all residues were in allowed regionsFigure 3 a. Coordination state of the calcium ion as found in
the three-dimensional structures of human enzyme, as well as
in rabbit and rat enzymes. b. Interactions observed between the
chloride ion of human, rabbit, and rat enzymes. The ligand
interaction module of MOE.2009.10 has been used to obtain the
two-dimensional schematic representation of the residues
positioned in the vicinity of the ions. In order to provide a better
feeling of the three-dimensional arrangement of the shown residues
in the case of chloride, this site is shown in rabbit enzyme, with
chloride ion shown as a sphere, and nearby amino acids as ball and
sticks. Colour codes of amino acids are as follows: basic residues in
pink with blue border, acidic residues in pink with red border, polar
residues in pink, hydrophobic (greasy) residues in green.
Figure 4 Scheme of the seven-ring containing ligand containing an acarviostatin derivative and a thiohydantoin-like moiety.
Numbering of the rings is arbitrary and has been done in order to facilitate description of its interactions.
Khalil-Moghaddam et al. DARU Journal of Pharmaceutical Sciences 2012, 20:77 Page 5 of 9
http://www.darujps.com/content/20/1/77and the only outlier was N378, where RPA had 100%
(490/490) of all its residues in the allowed region, with
no outlier in the structure. HPA, RPA and RABPA pos-
sess five conserved disulfide bonds, which correspond
to residues pairs 28–86, 70-115, 141–160, 378–384,
450–462 in HPA and RABPA, and residues pairs 28–86,
70-115,141-157,375-381, and 447–459 in RPA, in which
the numbering is altered due to the three-residue gap. It
should be mentioned that the numbering here has been
made according to the putative expressed protein (with
omission of the signal peptide, by comparison with
HPA_see Figure 1). In light of these quality assessment
results, and with regard to the high similarity of the
templates with the modeled targets, we believe thatFigure 5 Results of the potential energy versus time, obtained for a 5
pancreatic amylase containing the seven-ringed ligand.these models could be considered to have enough accur-
acy and biological plausibility for further ligand binding
studies.
The superimposed minimized backbone structures of
the three enzymes are shown in Figure 2, where the
three domains of the enzymes (A-C) are indicated.
Positioning of the calcium and chloride ions are related
to the human one, and could be assumed to be similar
in RPA and RABPA. The nearby residues interacting
with these ions are shown in Figure 3a and b for com-
parison means and indicate no major difference between
the three enzymes, a fact that is a further indication of
the biological plausibility of the models. The calcium ion
of HPA makes its interactions with the residues of000 picoseconds molecular dynamics simulation of human
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to Domain A [20]. This ion is considered to be “a central
organizing structural feature of Domain B” [24], is needed
for alpha-amylase catalytic activity, and its binding pocket
is essential to maintain the fold stability [25]. The chloride
ion was previously thought to be a feature of mammalian
amylase, and shown to possess activating property [26]. In
a thorough study to characterize the chloride binding
pocket of alpha-amylases, the anion was found to be
coordinated by one arginine, one arginine/lysine and
an asparagine residue throughout chloride-dependent
amylases, with R337 (PPA numbering) being a key fea-
ture for the anion binding [27].
The three missing residues detected in the rat sequence
are found to be located in a loop of domain B, which
makes the loop distinctively shorter in RPA (Figure 2).
In the next stage, a putative inhibitor was designed to as-
sess the differences of active site ligand binding between
the two models. As previously mentioned, acarviostatin-Figure 6 Acarviostatin AIV03-derivated ligand interactions within the
drawn with the use of MOE.2009.10 ligand-interaction module. Water mole
(6.b) in order to assess their potential significance in ligand-protein interac
HOH 586 (E233, catalytic residue), HOH 791 (N105),HOH 817 (I235) and HOH
hydrogen bonds (indicated by arrows, green arrows indicate side chain do
acceptors). Colour codes of amino acids are as follows: basic residues in pin
residues in pink, hydrophobic (greasy) residues in green.derived products have been reported as potent inhibitors
of HPA, and occupancy of seven subsites of HPA active site
suggested to be an efficient mean to inhibit the enzyme
[28]. On the other hand, acarviosinyl-isomaltosyl-spiro-
thiohydantoin has also been previously designed and tested
as a potent inhibitor of mammalian amylase [29]. Thus, a
hybrid compound structure was designed which contained
these two potent moieties. The ligand is composed of a
six carbohydrate-based units (as found in the crystal
structure 3OLI.pdb), with an added moiety resembling
thiohydantoin (Figure 4) in order to be able to fill the
seven subsites. Thiohydantoin contains one additional
nitrogen atom that was omitted here in order to make a
more hydrophobic structure. The compound was manu-
ally implemented in the 3OLI.pdb structure by supe-
rimposition to the existing ligand. However, a further
testing was done with a docking tool (Autodock vina) in
order to have an approval for the location of the ligand.
The docking method was first assessed with a dockinghuman enzyme in the 3OLI.pdb files. Interaction diagrams were
cules of the 3OLI.pdb structures have been preserved (6.a) or deleted
tions. Water molecules that are in the vicinity of amino acids are as
832 (A307). Interaction between residues and ligand moieties are
nors and acceptors and blue arrows indicate backbone donors and
k with blue border, acidic residues in pink with red border, polar
Figure 7 Interactions of the seven-ringed ligand with
subsite −4 of the three pancreatic enzymes. Colour codes of
amino acids are as follows: basic residues in pink with blue border,
acidic residues in pink with red border, polar residues in pink,
hydrophobic (greasy) residues in green. a. Interactions obtained with
the ligand after 5000 picoseconds of simulation. The water network
seems to be of importance in the interactions between ring number
1 and subsite −4 of the human enzyme. b. Residues found in the
vicinity (5Å) of the seven-ringed ligand in human pancreatic
enzyme. c. Superimposition of the interacting residues found in
human enzyme, with the ones of rabbit and rat enzymes. Residues
shown in black are different with the human enzyme in the rabbit
and rat models.
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Å was obtained between the best pose obtained by docking
and the actual binding mode. This is satisfactory with re-
gard to the less than 2 Å threshold usually used to assess
successful docking [30], and especially with regard to the
large size and multiple rotatable bonds of the ligand.
Results of the proposed compound docking showed that
the first docked pose was comparable to the manually
positioned ligand, but the latter was further used, since
derived from a crystallographically obtained pose.
In order to get an approximation of the possible effect-
iveness of this ligand as a potential inhibitor of the en-
zyme, docking score was obtained for the HPA co-
crystallized pseudo saccharide ligand acarviostatin II03
(with 7 carbohydrate-based units). This score was −14.6
kcal/mol for acarviostatin II03 while our ligand achieved a
−13.4 kcal/mol. In comparison, acarbose (with four units)
had a score of −11 kcal/mol. The Ki of acarviostatin II03
is reported to be of 0.0147 μM and the Ki of acarbose that
is around 2.6 μM [28], which is suggesting that our ligand
could be potentially better than acarbose, but this assump-
tion remains to be verified.
A short molecular dynamics simulation was then per-
formed to get an insight of the interaction of the ligand
with flexible active site residues in an aqueous environ-
ment. It should be mentioned that this simulation was ran
as an alternative to flexible docking, for 5000 picoseconds
which is acceptable in these cases [31,32]. The system po-
tential energy is shown in Figure 5 and is indicative of an
equilibrated stage in the last 1000 picoseconds.
The seven active cleft subsites occupied by the original
ligands span from the −4 subsite to the +3 one. Based on
in vitro inhibition studies on acarviostatin derivatives, the
−4 subsite has been particularly highlighted as a location
whose occupation would increase the potency of designed
inhibitors [18]. It is interesting to note that interaction of
the original ligand with both −4 and +3 subsites occurs
mainly through water molecules. Figure 6 shows an inter-
action diagram obtained with MOE.2009.10 when the solv-
ent molecules of the 3OLI.pdb file were present or absent.
As observed in Figure 6a, interaction of the ligand with
subsite −4 N105 and D147 occurs via water molecules.
Similarly, subsite +3 interactions are also happening via
water molecule (in this structure). When water molecules
are deleted, and the interaction diagram redrawn (Figure
6b), the two ending moieties of the ligand show no particu-
lar interactions.
In the case of our ligand, the interactions that occur in
the final frame of the simulation are shown in Figure 7a.
Residues related to subsite −4 that surround ring 1 of
the ligand (see Figure 4) include I51, Q63, G104, A106,
V107 and G164 (shown in Figure 7b) and seem to make
a hydrophobic pocket. The hydrogen bond that occurs
between Q63 and the ligand, as well as the interactionwith T163 are also of interest. In order to compare the
corresponding residues of RABPA and RPA enzymes
related to the subsite −4, a superimposition of the most
important residues was done (Figure 7c).
Residues N53, Q63 and G104 are conserved in all three
enzymes. However, V51 replaces I51 in RABPA, but it is
conserved in RPA as I51. As observed in Figure 7b, this
makes a shorter side chain in this place for RABPA, and
consequently, more space exists in this location. Instead of
A106, both RABPA and RPA possess G106, again with the
consequence of providing more available space in that
position. The most important difference occurs in V107,
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RPA. This is a more radical change, which results in polar,
and bulkier side chains taking the place of an aliphatic side
chain. Thus, a potential designed ligand possessing a bulk-
ier moiety in place of ring 1 of our ligand could probably
fail to interact properly in this region with RABPA or
RPA, while it might have in fact a good positioning in the
human enzyme. Reversely, if some designed ligand find
enough space in the vicinity of residues 106 or 51 in
RABPA or RPA, it may be too large for HPA. A review of
the other residues that are interacting with rings 2–7 of
the ligands (based on the diagram shown in Figure 7a)
shows their perfect conservation in the three enzymes,
with the exception of T163 being replaced by a serine resi-
due in RPA, while remaining T163 in RABPA.
Conclusion
Overall, the structural differences between RPA and HPA
could be assessed to be more important than the ones
between RABPA and the human enzyme, with regard to
inhibitor design. Especially, the shortening of a loop in do-
main B of rat enzyme should be highlighted, as it may pro-
duce long-range effect in case of conformational changes.
About the active site itself, if ligands are to be designed that
would span subsites −3 to +3, RABPA would be a better
choice for testing the compounds, and consequently, rabbit
would be a better model in this regard. If a ligand present a
structure capable of interacting with subsite −4, then
results obtained from the use of both RABPA and RPA
(and the animals themselves) could be different with the
results obtained for the human enzyme. Since modeling
techniques have now evolved to become more accessible, it
would be advisable to use them in order to assess the pos-
sible positive/negative outcome of tests in animal models.
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